Skip to main content

Table 2 Change in hemoglobin from baseline to Week 13

From: Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

 

QW

EDS

Difference

 

(n = 374)

(n = 378)

(QW - EDS)

LVCF method

   

   na

374

375

 

   Least squares mean (95% CI)

0.90 (0.74, 1.07)

0.95 (0.79, 1.11)

-0.04 (-0.26, 0.17)b

Available data method

   

   na,c

257

253

 

   Least squares mean (95% CI)

1.29 (1.10, 1.47)

1.16 (0.98, 1.34)

0.13 (-0.11, 0.36) b

  1. aThree patients in the EDS group were missing screening hemoglobin and were omitted from the ANOVA model
  2. bThe least squares means and CIs of the treatment difference were computed from an ANOVA model after adjusting for the stratification factors at randomization (chemotherapy cycle length, screening hemoglobin, and tumor type)
  3. cPatients missing hemoglobin values at Week 13 were omitted from the analysis
  4. QW = once weekly; EDS = extended dosing schedule; LVCF = last value carried forward; CI = confidence interval; ANOVA = analysis of variance
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us